What one share of Retinalgenix Technologies holds
Retinalgenix Technologies’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.11 |
|---|---|
| Cash and investments | $0.00 |
| Debt | $0.00 |
| Book value | −$0.14 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | — | −$0.25 | — | — | — | −$0.06 |
| 2023 | — | −$0.12 | — | — | — | −$0.08 |
| 2024 | — | −$0.24 | — | — | — | −$0.08 |
| 2025 | — | −$0.13 | — | — | — | −$0.12 |
Common questions about Retinalgenix Technologies
How much does one share of Retinalgenix Technologies earn?
Over the last 12 months, Retinalgenix Technologies lost $0.11 for each share.
Does Retinalgenix Technologies pay a dividend?
Retinalgenix Technologies didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Retinalgenix Technologies’s book value per share?
Retinalgenix Technologies’s book value is negative (−$0.14 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Retinalgenix Technologies have?
Each share of Retinalgenix Technologies has $0.00 of cash and investments and $0.00 of debt, as of June 30, 2026.
Has Retinalgenix Technologies bought back shares?
Retinalgenix Technologies’s share count rose about 19% from 2022 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.